MedTrace Logo

Expression and Role of the JAK/STAT Pathway in Sarcoidosis Granuloma Cells

NCT04751279 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2023-11-18

No results posted yet for this study

Summary

Recent studies suggest that the JAK/STAT signaling pathway constitutes a new step in the clinical and therapeutic progress of sarcoidosis. Further investigations are necessary to identify the most suitable patients to receive treatment targeting this pathway, in particular in cases of severe sarcoidosis refractory to the various therapeutic lines.

Conditions

  • Sarcoidosis
  • JAK-STAT Pathway Deregulation

Interventions

OTHER

Blood sample

Blood sample collection of 5 blood sample at the inclusion in the study the samle consite of 5 tubesEthylene Diamine Tetra Acetate (ADTA) of 7 ml

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Florence JENY, MD · Assistance Publique - Hôpitaux Paris

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-09
Primary Completion
2024-01-01
Completion
2024-01-02

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04751279 on ClinicalTrials.gov